Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
OROramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP)

NASDAQ Capital Market · Currency in USD
$4.13 ▲ +0.01 (+0.24%)
At close: Oct 23, 4:00 PM ET. Market closed.
$4.13 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$4.12
Open
$4.22
Day's Range
$4.07 – $4.22
52 Week Range
$2.09 – $5.47
Volume
115,662
Avg. Volume
271,819
Market Cap
$171.80M
Beta (5Y Monthly)
1.28
PE Ratio (TTM)
0.98
EPS (TTM)
$4.26
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Jan 16, 2026
1y Target Est
--

Profile: Oramed Pharmaceuticals Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
13
CEO
Nadav Kidron
Website
oramed.com

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate $0.43
DateEst.Actual
Aug 10, 2026$0.43$2.76Beat
May 19, 2026–$0.91
Mar 26, 2026-$0.08-$0.06Beat
Nov 13, 2025-$0.04$1.13Beat
Aug 14, 2025-$0.04-$0.05Miss
May 15, 2025-$0.03-$0.19Miss

Analyst view

Rating: Buy
Buy 75% · Hold 25% · Sell 0%

Get free alerts on ORMP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.